SCHEMBL16611740

SCHEMBL16611740

O=C1OCCN1Cc1ccc(-c2nn(-c3c(F)cccc3F)c3c(Cl)c[nH]c(=O)c23)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.37
GRM2 Q14416 7/20 0.35
GRIN1 Q05586 2/20 0.35
GRIN2B Q13224 2/20 0.35
NR1I2 O75469 1/20 0.35
KCNH2 Q12809 1/20 0.35
TNIK Q9UKE5 2/20 0.34
AURKA O14965 1/20 0.33
FLT1 P17948 1/20 0.33
GCK P35557 1/20 0.33
FLT4 P35916 1/20 0.33
MAP3K11 Q16584 1/20 0.33
STK17A Q9UEE5 1/20 0.33
CNR1 P21554 2/20 0.33
HTR2A P28223 1/20 0.32
ALDH1A1 P00352 2/20 0.32
MAPK1 P28482 1/20 0.32
FGFR1 P11362 1/20 0.32
FGFR2 P21802 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16610943 0.86 CYP2A13 (0.42) ALDH1A1KDM4EHPGDLMNA
SCHEMBL16611245 0.85 GRIA2 (0.39) LTA4HGRM2KCNH2AURKAFLT1
SCHEMBL16610908 0.83 DCTPP1 (0.35) GRM2ALDH1A1
SCHEMBL16611103 0.82 KDM4E (0.43) ALDH1A1KDM4EHPGD
Hydrochloric Acid SCHEMBL16611325 0.82 KDM4E (0.43) ALDH1A1KDM4EHPGD
SCHEMBL16611157 0.82 KCNJ5 (0.34) CNR1
SCHEMBL16611193 0.79 PDGFRB (0.42) ALDH1A1KDM4EHPGD
SCHEMBL16611258 0.79 KCNJ5 (0.35) CNR1
SCHEMBL16610919 0.78 JAK2 (0.36) ALDH1A1KDM4EHPGD
SCHEMBL16611172 0.78 SCN9A (0.35) ALDH1A1KDM4EHPGDSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-9371320-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
EP-2857400-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160251352-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 LTA4H 3800/4885GRM2 3878/4885GRIN1 4272/4885
US-20150141406-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 LTA4H 3800/4885GRM2 3878/4885GRIN1 4272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.